2021-08-012022-07-312022-07-31false03433979KINGSTOWN HEALTHCARE INVESTMENTS LIMITED2022-08-31iso4217:GBPxbrli:pure034339792021-08-01034339792022-07-31034339792021-08-012022-07-31034339792020-08-01034339792021-07-31034339792020-08-012021-07-3103433979bus:SmallEntities2021-08-012022-07-3103433979bus:AuditExempt-NoAccountantsReport2021-08-012022-07-3103433979bus:FullAccounts2021-08-012022-07-3103433979bus:PrivateLimitedCompanyLtd2021-08-012022-07-3103433979core:WithinOneYear2022-07-3103433979core:AfterOneYear2022-07-3103433979core:WithinOneYear2021-07-3103433979core:AfterOneYear2021-07-3103433979core:ShareCapital2022-07-3103433979core:SharePremium2022-07-3103433979core:RevaluationReserve2022-07-3103433979core:OtherReservesSubtotal2022-07-3103433979core:RetainedEarningsAccumulatedLosses2022-07-3103433979core:ShareCapital2021-07-3103433979core:SharePremium2021-07-3103433979core:RevaluationReserve2021-07-3103433979core:OtherReservesSubtotal2021-07-3103433979core:RetainedEarningsAccumulatedLosses2021-07-3103433979core:LandBuildings2022-07-3103433979core:PlantMachinery2022-07-3103433979core:Vehicles2022-07-3103433979core:FurnitureFittings2022-07-3103433979core:OfficeEquipment2022-07-3103433979core:NetGoodwill2022-07-3103433979core:IntangibleAssetsOtherThanGoodwill2022-07-3103433979core:ListedExchangeTraded2022-07-3103433979core:UnlistedNon-exchangeTraded2022-07-3103433979core:LandBuildings2021-07-3103433979core:PlantMachinery2021-07-3103433979core:Vehicles2021-07-3103433979core:FurnitureFittings2021-07-3103433979core:OfficeEquipment2021-07-3103433979core:NetGoodwill2021-07-3103433979core:IntangibleAssetsOtherThanGoodwill2021-07-3103433979core:ListedExchangeTraded2021-07-3103433979core:UnlistedNon-exchangeTraded2021-07-3103433979core:LandBuildings2021-08-012022-07-3103433979core:PlantMachinery2021-08-012022-07-3103433979core:Vehicles2021-08-012022-07-3103433979core:FurnitureFittings2021-08-012022-07-3103433979core:OfficeEquipment2021-08-012022-07-3103433979core:NetGoodwill2021-08-012022-07-3103433979core:IntangibleAssetsOtherThanGoodwill2021-08-012022-07-3103433979core:ListedExchangeTraded2021-08-012022-07-3103433979core:UnlistedNon-exchangeTraded2021-08-012022-07-3103433979core:MoreThanFiveYears2021-08-012022-07-3103433979core:Non-currentFinancialInstruments2022-07-3103433979core:Non-currentFinancialInstruments2021-07-3103433979dpl:CostSales2021-08-012022-07-3103433979dpl:DistributionCosts2021-08-012022-07-3103433979dpl:AdministrativeExpenses2021-08-012022-07-3103433979core:LandBuildings2021-08-012022-07-3103433979core:PlantMachinery2021-08-012022-07-3103433979core:Vehicles2021-08-012022-07-3103433979core:FurnitureFittings2021-08-012022-07-3103433979core:OfficeEquipment2021-08-012022-07-3103433979core:NetGoodwill2021-08-012022-07-3103433979core:IntangibleAssetsOtherThanGoodwill2021-08-012022-07-3103433979dpl:GroupUndertakings2021-08-012022-07-3103433979dpl:ParticipatingInterests2021-08-012022-07-3103433979dpl:GroupUndertakingscore:ListedExchangeTraded2021-08-012022-07-3103433979core:ListedExchangeTraded2021-08-012022-07-3103433979dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-08-012022-07-3103433979core:UnlistedNon-exchangeTraded2021-08-012022-07-3103433979dpl:CostSales2020-08-012021-07-3103433979dpl:DistributionCosts2020-08-012021-07-3103433979dpl:AdministrativeExpenses2020-08-012021-07-3103433979core:LandBuildings2020-08-012021-07-3103433979core:PlantMachinery2020-08-012021-07-3103433979core:Vehicles2020-08-012021-07-3103433979core:FurnitureFittings2020-08-012021-07-3103433979core:OfficeEquipment2020-08-012021-07-3103433979core:NetGoodwill2020-08-012021-07-3103433979core:IntangibleAssetsOtherThanGoodwill2020-08-012021-07-3103433979dpl:GroupUndertakings2020-08-012021-07-3103433979dpl:ParticipatingInterests2020-08-012021-07-3103433979dpl:GroupUndertakingscore:ListedExchangeTraded2020-08-012021-07-3103433979core:ListedExchangeTraded2020-08-012021-07-3103433979dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-08-012021-07-3103433979core:UnlistedNon-exchangeTraded2020-08-012021-07-3103433979core:NetGoodwill2022-07-3103433979core:IntangibleAssetsOtherThanGoodwill2022-07-3103433979core:LandBuildings2022-07-3103433979core:PlantMachinery2022-07-3103433979core:Vehicles2022-07-3103433979core:FurnitureFittings2022-07-3103433979core:OfficeEquipment2022-07-3103433979core:AfterOneYear2022-07-3103433979core:WithinOneYear2022-07-3103433979core:ListedExchangeTraded2022-07-3103433979core:UnlistedNon-exchangeTraded2022-07-3103433979core:ShareCapital2022-07-3103433979core:SharePremium2022-07-3103433979core:RevaluationReserve2022-07-3103433979core:OtherReservesSubtotal2022-07-3103433979core:RetainedEarningsAccumulatedLosses2022-07-3103433979core:NetGoodwill2021-07-3103433979core:IntangibleAssetsOtherThanGoodwill2021-07-3103433979core:LandBuildings2021-07-3103433979core:PlantMachinery2021-07-3103433979core:Vehicles2021-07-3103433979core:FurnitureFittings2021-07-3103433979core:OfficeEquipment2021-07-3103433979core:AfterOneYear2021-07-3103433979core:WithinOneYear2021-07-3103433979core:ListedExchangeTraded2021-07-3103433979core:UnlistedNon-exchangeTraded2021-07-3103433979core:ShareCapital2021-07-3103433979core:SharePremium2021-07-3103433979core:RevaluationReserve2021-07-3103433979core:OtherReservesSubtotal2021-07-3103433979core:RetainedEarningsAccumulatedLosses2021-07-3103433979core:NetGoodwill2020-08-0103433979core:IntangibleAssetsOtherThanGoodwill2020-08-0103433979core:LandBuildings2020-08-0103433979core:PlantMachinery2020-08-0103433979core:Vehicles2020-08-0103433979core:FurnitureFittings2020-08-0103433979core:OfficeEquipment2020-08-0103433979core:AfterOneYear2020-08-0103433979core:WithinOneYear2020-08-0103433979core:ListedExchangeTraded2020-08-0103433979core:UnlistedNon-exchangeTraded2020-08-0103433979core:ShareCapital2020-08-0103433979core:SharePremium2020-08-0103433979core:RevaluationReserve2020-08-0103433979core:OtherReservesSubtotal2020-08-0103433979core:RetainedEarningsAccumulatedLosses2020-08-0103433979core:AfterOneYear2021-08-012022-07-3103433979core:WithinOneYear2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:CostValuation2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-08-012022-07-3103433979core:Non-currentFinancialInstrumentscore:CostValuation2022-07-3103433979core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-07-3103433979core:Non-currentFinancialInstrumentscore:CostValuation2021-07-3103433979core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-07-3103433979core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-07-3103433979bus:Director12021-08-012022-07-31

KINGSTOWN HEALTHCARE INVESTMENTS LIMITED

Registered Number
03433979
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2022

KINGSTOWN HEALTHCARE INVESTMENTS LIMITED
Company Information
for the year from 1 August 2021 to 31 July 2022

Directors

FITCH, Michael Craig

Registered Address

222 Quadrangle Tower
Cambridge Square
London
W2 2PJ

Registered Number

03433979 (England and Wales)
KINGSTOWN HEALTHCARE INVESTMENTS LIMITED
Balance Sheet as at
31 July 2022

Notes

2022

2021

£

£

£

£

Fixed assets
Tangible assets67,521,5577,448,101
7,521,5577,448,101
Current assets
Debtors8169,985303,754
Cash at bank and on hand659,043504,128
829,028807,882
Creditors amounts falling due within one year9(187,990)(194,555)
Net current assets (liabilities)641,038613,327
Total assets less current liabilities8,162,5958,061,428
Creditors amounts falling due after one year10(2,764,840)(2,881,539)
Provisions for liabilities11(384,752)(368,725)
Net assets5,013,0034,811,164
Capital and reserves
Called up share capital10,00010,000
Revaluation reserve3,485,2883,431,473
Profit and loss account1,517,7151,369,691
Shareholders' funds5,013,0034,811,164
The financial statements were approved and authorised for issue by the Director on 31 August 2022, and are signed on its behalf by:
FITCH, Michael Craig
Director
Registered Company No. 03433979
KINGSTOWN HEALTHCARE INVESTMENTS LIMITED
Notes to the Financial Statements
for the year ended 31 July 2022

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The principal activity of the company continued to be nursing home property holding.
4.Accounting policies
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Investment property policy
Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in the Statement of Comprehensive Income.
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation and operations policy
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Valuation of financial instruments policy
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan. Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income. For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.
Going concern
The financial statements have been prepared on a going concern basis.
5.Employee information

20222021
Average number of employees during the year11
6.Property, plant and equipment

Land & buildings

Total

££
Cost or valuation
At 01 August 217,448,1017,448,101
Additions19,64219,642
Revaluations53,81453,814
At 31 July 227,521,5577,521,557
Net book value
At 31 July 227,521,5577,521,557
At 31 July 217,448,1017,448,101
On 6th October 2020, the company property, Harwood House, was professionally valued by Christie & Co in accordance with the RICS Valuation - Global Standards (the "Red Book"), incorporating the International Valuation Standards ("IVS"), both effective from 31st January 2020. In Christie & Co's opinion, the Market Value of the Freehold Interest in the Property in its existing use and present condition as a fully equipped and operating entity, having regard to its trading potential as at the valuation date is £7,900,000. As at the Balance Sheet date, £7,521,557 is held within the books of Kingstown Healthcare Investments Limited with the balance (£378,443) being held within the books of Harwood House Limited.
7.Description of nature of transactions and balances with related parties
The parent company is Peterock Limited, a company registered in England. During the year sales amounting to £572,215 (2021: £560,995) were made to related parties and purchases amounting to £44,073 (2021: £nil) were made from related parties. At the Balance Sheet date £nil (2021: £1,348) was owed from related parties and £2,741 (2021: £25,495) was owed to related parties.
8.Debtors

2022

2021

££
Trade debtors / trade receivables-274,361
Amounts owed by group undertakings-1,348
Other debtors2,4534,607
Prepayments and accrued income167,53219,588
Deferred tax asset, debtors (Non-current)-3,850
Total169,985303,754
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
9.Creditors within one year

2022

2021

££
Trade creditors / trade payables8,3519,239
Bank borrowings and overdrafts116,699110,884
Amounts owed to related parties2,74225,495
Taxation and social security20,127-
Accrued liabilities and deferred income40,07148,937
Total187,990194,555
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
10.Creditors after one year

2022

2021

££
Bank borrowings and overdrafts2,764,8402,881,539
Total2,764,8402,881,539
Details of security provided: Charges to the Bank (for itself and any relevant company within the Bank group: 1.) A first legal charge over Harwood House. 2.) A first, fixed and floating charge over all assets of the company. 3.) A first, fixed and floating charge over all assets of Harwood House Limited. 4.) A Deed of Assignment over Rental Income. 5.) A cross company guarantee of Peterock Limited and Harwood House Limited.
11.Provisions for liabilities

2022

2021

££
Net deferred tax liability (asset)384,752368,725
Total384,752368,725